Regeneron: Time To Forget Fianlimab (Rating Upgrade)
Regeneron Pharmaceuticals has received a rating upgrade despite setbacks from its fianlimab and Libtayo trials. The company is viewed as a strong buy due to its robust growth prospects and a solid pipeline. Analysts believe that the recent failures will not significantly impact Regeneron's long-term value.
- ▪Regeneron faced a setback after fianlimab and Libtayo failed in a phase 3 trial in first-line metastatic melanoma.
- ▪These results have negative implications for other fianlimab-based trials in melanoma.
- ▪Analysts see Regeneron as a strong buy following the pullback, as fianlimab-based combinations were not critical for long-term value creation.
Seeking Alpha files mainly under finance. We currently carry 6,312 of its stories.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4906080-regeneron-time-to-forget-fianlimab-rating-upgrade"},"author":{"@type":"Person","name":"ONeil…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
